Prostate Cancer Coverage from Every Angle


RALU Study: Impact of Sequencing Radionuclide Therapies on Outcomes in Prostate Cancer
Second-Generation AR Inhibitors in Prostate Cancer: Findings From the Real-World DEAR Trial
Final Overall Survival Data From PROpel on Abiraterone Plus Olaparib in Metastatic Prostate Cancer
AR Inhibitor Plus Androgen-Deprivation Therapy in Prostate Cancer: ARASENS Update on Disease Volume and Risk
Can Plant-Based Diets Reduce the Risk of Prostate Cancer Progression?
Adding Pembrolizumab to Docetaxel in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2023: Hormone Therapy Plus an Anti-PSMA Antibody Labeled With Lu-177 in Nonmetastatic Prostate Cancer
SAKK 08/16 Results Show Benefit of Darolutamide Maintenance in Metastatic Prostate Cancer
ASCO GU 2023: Combination Treatment With Niraparib for Subset of Metastatic Prostate Cancer
Recruitment Opens for PRESERVE Trial: Focal Therapy May Be Alternative to Surgery
ASCO GU 2023: PSA Response to Darolutamide Monotherapy in Hormone-Naive Prostate Cancer
ASCO GU 2023: Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2023: Androgen Deprivation, Darolutamide, and Ipatasertib for Castration-Resistant Prostate Cancer
ASCO GU 2023: Adding Hormone Therapy Plus an Antiandrogen to Salvage Therapy for High-Risk Prostate Cancer
ASCO GU 2023: Use of Darolutamide in a Racially Diverse Patient Population With Metastatic Prostate Cancer
ASCO GU 2023: Nivolumab Plus Ipilimumab After Chemotherapy for Resistant Prostate Cancer
ASCO GU 2023: Rucaparib Versus Docetaxel or Second-Generation Androgen Pathway Inhibition in Metastatic Prostate Cancer
Study Finds Skin Color Seems to Matter in Prostate Cancer Treatment Offerings
Can Lymph Node Degeneration Impact Metastasis of Prostate Cancer?
Comparing the Use of PET/MRI and PET/MRI With PSMA in Radiotherapy for High-Risk Prostate Cancer
Internet-Based Germline Genetic Testing in Metastatic Prostate Cancer: More Accessible for Patients?
Prostate Cancer Screening Practices in Transgender Patients
Focused Treatment of Solitary Prostate Cancer Metastases Without Hormone Blockers
Prostate Cancer Cell Lines: Brazilian Berry Extract and Immune Responses
Can Overdiagnosis of Prostate Cancer Be Reduced With MRI-Directed Screening? Researchers Say Yes
Can Single-Port Robotic Surgery Improve Cosmesis After Prostate Surgery?
FOXA1: Potential Therapeutic Target in Castration-Resistant Prostate Cancer?
ESMO Asia 2022: Genomic Differences in Prostate Cancer Among Chinese Patients
Novel Gene Signature May Predict the Risk of Lineage Plasticity in Prostate Tumors
ASTRO 2022: Quality of Life and Quantity of Life in Patients With Prostate Cancer
ASTRO 2022: Assessing Sexual Dysfunction After Brachytherapy for Genitourinary Cancers
ASTRO 2022: Sequencing of Short-Term Androgen-Deprivation Therapy With Radiotherapy for Prostate Cancer
ASTRO 2022: Salvage Radiotherapy Plus Enzalutamide for High-Risk Prostate Cancer After Prostatectomy
SITC 2022: Phase II Study of Vudalimab for Metastatic Castration-Resistant Prostate Cancer
ASTRO 2022: Hypofractionated Radiotherapy for High-Risk Prostate Cancer
ASTRO 2022: Using 24-Gene Score to Predict Outcomes With Salvage Radiotherapy After Radical Prostatectomy
ASTRO 2022: Is There a Correlation Between PSA Screening and Subsequent Metastatic Prostate Cancer?
ASTRO 2022: Combining Hormone Therapy and Metastasis-Directed Radiotherapy for Advanced Prostate Cancer
ASTRO 2022: Multimodal Deep Learning Versus NCCN Risk Stratification of Prostate Cancer
ASTRO 2022: PSMA PET/CT and Its Impact on Prostate Cancer Salvage Radiation Therapy Management
Targeted Imaging With PSMA Tracer May Alter Treatment Plans for Some Patients With Prostate Cancer
Oligometastatic Prostate Cancer: Do Genomic Alterations Have Prognostic Value?
BET Inhibitor Under Study in Metastatic Castration-Resistant Prostate Cancer
ASCO Quality 2022: An Education Initiative That Aims to Improve Equity in Prostate Cancer Screening
Genomic Classifiers as Prognostic Factors for Androgen-Deprivation Therapy for Advanced Prostate Cancer
Targeting Myeloid Chemotaxis in Resistant Metastatic Prostate Cancer
ASCO Quality 2022: Tailored Self-Managed Care for Survivors of Prostate Cancer
Biomarker Analysis From PROpel Trial of Abiraterone Plus Olaparib in Advanced Prostate Cancer
African Ancestry and Genetic Variants in Prostate Tumors

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.